AZ17: a new bispecific drug targeting IL-6 and IL-23 with potential clinical use—improves psoriasis in a human xenograft transplantation model-Reference-Cited by-同舟云学术

AZ17: a new bispecific drug targeting IL-6 and IL-23 with potential clinical use—improves psoriasis in a human xenograft transplantation model

Published:2015-08-12 Issue:10 Volume:28 Page:467-480
ISSN:1741-0126
Container-title:Protein Engineering Design and Selection
language:en
Short-container-title:Protein Engineering, Design and Selection

Author:

Stenderup Karin,Rosada Cecilia,Shanebeck Kurt,Brady William,Van Brunt Michael P.,King Gordon,Marelli Marcello,Slagle Paul,Xu Hengyu,Nairn Natalie W.,Johnson Jeffrey,Wang Aijun A.,Li Gary,Thornton Kenneth C.,Dam Tomas N.,Grabstein Kenneth H.

Funder

Allozyne

the Department of Dermatology, Aarhus University Hospital

the Institute of Clinical Medicine, Aarhus University

Publisher

Oxford University Press (OUP)

Subject

Molecular Biology,Biochemistry,Bioengineering,Biotechnology

Link

http://academic.oup.com/peds/article-pdf/28/10/467/17495296/gzv034.pdf

Reference67 articles.

1. Production of hybridoma growth factor by human monocytes

2. Interleukins 1β and 6 but not transforming growth factor-β are essential for the differentiation of interleukin 17–producing human T helper cells

3. Interleukin-23 Promotes a Distinct CD4 T Cell Activation State Characterized by the Production of Interleukin-17

4. PEG-modified biopharmaceuticals

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel bispecific nanobody mitigates experimental intestinal inflammation in mice by targeting TNF‐α and IL‐23p19 bioactivities;Clinical and Translational Medicine;2024-03

2. Targeting fusion proteins of the interleukin family: A promising new strategy for the treatment of autoinflammatory diseases;European Journal of Pharmaceutical Sciences;2024-01

3. Preclinical study models of psoriasis: State-of-the-art techniques for testing pharmaceutical products in animal and nonanimal models;International Immunopharmacology;2023-04

4. Plaque-type psoriasis inhibitors;International Immunopharmacology;2021-12

5. Dual inhibition of IL-17A and IL-17F in psoriatic disease;Therapeutic Advances in Chronic Disease;2021-01